Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02069925 · ClinicalTrials.gov registry record · NA
STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 285
- Enrollment target
NCT02069925 is a NA study that has completed, run by Yale University. The registered enrollment target is 285 participants.
The verdict
NCT02069925, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 285 participants
- Enrollment target
Study Summary
The guiding questions for this study are: can a U.S. adaptation of a successful Scandinavian approach (TIPS) to early detection substantially reduce the duration of untreated psychosis (DUP) and improve outcomes beyond an established first-episode service (FES)? The primary aim of this study is: 1. To determine whether an early detection intervention can reduce DUP in the US, as compared to usual detection. Early detection (ED) will be implemented in one US community (New Haven, CT), and usual detection efforts will continue in another (Boston, MA). DUP will be measured at admission to the corresponding first-episode services (STEP \& PREP) in each community, over one year before and throughout ED implementation. The investigators hypothesize that DUP will be reduced significantly in the early detection site compared to the usual detection site; 2. A secondary aim is to determine whether DUP reduction can augment the outcomes of established FES on outcomes in the U.S. The investigators will measure symptoms, functioning and engagement with treatment at entry and over 1 year at each site. The investigators hypothesize that shorter DUP at one FES (STEP) will predict reduced distress and illness severity at entry and better early outcomes at STEP compared to PREP.
Interventions
- BEHAVIORAL Early Detection (ED)
- BEHAVIORAL Usual Detection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2014-02-01 |
| Est. Completion | 2020-08-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02069925
The ClinicalTrials.gov registry entry for NCT02069925 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Early Detection (ED) is the first listed.
NCT02069925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02069925 about?
NCT02069925 is a clinical study titled "STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.". The guiding questions for this study are: can a U.S. adaptation of a successful Scandinavian approach (TIPS) to early detection substantially reduce the duration of untreated psychosis (DUP) and improve outcomes beyond an established first-episode service (FES)? The primary aim of this study is: 1...
What is the current status of trial NCT02069925?
This trial is currently completed. It is a NA study. The enrollment target is 285 participants. The study started on 2014-02-01. Estimated completion is 2020-08-18.
What interventions are being tested in trial NCT02069925?
The interventions under investigation include: Early Detection (ED) (BEHAVIORAL), Usual Detection (BEHAVIORAL).
Who is sponsoring clinical trial NCT02069925?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.